- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
- EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
- EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
- EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
- EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
- EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
- EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
More ▼
Key statistics
On Friday, MorphoSys AG (0NDV:LSE) closed at 14.65, 23.73% above the 52 week low of 11.84 set on Dec 16, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.06 |
---|---|
High | -- |
Low | -- |
Bid | 14.29 |
Offer | 15.02 |
Previous close | 15.22 |
Average volume | 35.69k |
---|---|
Shares outstanding | 34.23m |
Free float | 33.66m |
P/E (TTM) | -- |
Market cap | 501.33m EUR |
EPS (TTM) | -4.43 EUR |
Data delayed at least 20 minutes, as of Mar 31 2023 18:00 BST.
More ▼